No Data
No Data
No Data
No Data
No Data
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock.Vaxxinity shares di
BenzingaApr 22 13:26 ET
MRIN, WISA and SMFL Among Mid-day Movers
Seeking AlphaApr 22 12:52 ET
12 Health Care Stocks Moving In Monday's Intraday Session
GainersNKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's market cap stands at $33.7 million. The company's, Q4 earnings came out 4 days ago. MSP Rec
BenzingaApr 22 12:31 ET
Inhibikase Therapeutics Files to Sell Common Stock, Warrants
Seeking AlphaApr 19 17:26 ET
Inhibikase Therapeutics Updates Shareholders on Future Plans
TipRanksApr 19 06:13 ET
Express News | Inhibikase Therapeutics - Upon Completion of Double-Blinded Phase of 201 Trial, We Expect to Request an End of Phase 2 Meeting With FDA by End of 2024
Moomoo 24/7Apr 18 16:30 ET
Jaguar8 : Love this!
TrytosaveabitOP Jaguar8: Yup yup! I kinda dig it as well!
taijahmed75 TrytosaveabitOP: do you know any reason for the big fall today? Such a good stock….
TrytosaveabitOP taijahmed75: Im guessing it because they said to shareholders Friday there is a big concern whether they will have enough money to continue
taijahmed75 TrytosaveabitOP: Oh ok, thank you
TrytosaveabitOP : We were pleased with the discussion we had with the FDA as we begin the process of building our first NDA package needed for approval," said Dr. Milton Werner, President and Chief Executive Officer of Inhibikase. "Our bioequivalence studies were presented to the FDA and we were given specific guidance on the manufacturing requirements necessary to complete the NDA. The FDA acknowledged that the appropriate approval path appears to be 505(b)(2) and we plan to seek all 11 indications for which imatinib mesylate has been approved, including its use in children. There is significant work ahead of us as we discuss these details with potential commercialization partners and carry out the work needed for the NDA submission," noted Dr. Werner.
No Data
No Data